Search Results - "Finn, Richard S"

Molecular therapies for HCC: Looking outside the box by Faivre, Sandrine, Rimassa, Lorenza, Finn, Richard S.

“…Over the past decade, sorafenib has been the only systemic agent with proven clinical efficacy for patients with unresectable hepatocellular carcinoma (HCC)…”
Get full text

Evolution of Systemic Therapy for Hepatocellular Carcinoma by Finn, Richard S., Zhu, Andrew X.

“…Despite being one of the leading causes of cancer death globally, hepatocellular carcinoma (HCC) has historically not been the focus of novel drug development…”
Get full text

Advances in targeted therapies for hepatocellular carcinoma in the genomic era by Llovet, Josep M., Villanueva, Augusto, Lachenmayer, Anja, Finn, Richard S.

“…Key Points The global incidence of liver cancer is increasing, with reports indicating that disease-specific mortality has doubled in the past 20 years…”
Get full text

Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases by Marrero, Jorge A., Kulik, Laura M., Sirlin, Claude B., Zhu, Andrew X., Finn, Richard S., Abecassis, Michael M., Roberts, Lewis R., Heimbach, Julie K.

Get full text

The Role of Angiogenesis in Hepatocellular Carcinoma by Morse, Michael A, Sun, Weijing, Kim, Richard, He, Aiwu Ruth, Abada, Paolo B, Mynderse, Michelle, Finn, Richard S

“…Hepatocellular carcinoma (HCC) accounts for about 90% of all primary liver cancers and is the second leading cause of cancer-related deaths worldwide. The…”
Get full text

Hepatocellular Carcinoma: Pick the Winner-Tyrosine Kinase Inhibitor Versus Immuno-oncology Agent-Based Combinations by Bejjani, Anthony C, Finn, Richard S

“…The treatment landscape for advanced hepatocellular carcinoma has changed dramatically over the past 4 years. We now have numerous options for patients in…”
Get full text

Palbociclib and Letrozole in Advanced Breast Cancer by Finn, Richard S, Martin, Miguel, Rugo, Hope S, Jones, Stephen, Im, Seock-Ah, Gelmon, Karen, Harbeck, Nadia, Lipatov, Oleg N, Walshe, Janice M, Moulder, Stacy, Gauthier, Eric, Lu, Dongrui R, Randolph, Sophia, Diéras, Véronique, Slamon, Dennis J

“…Among women with previously untreated hormone-receptor–positive advanced breast cancer, the addition of the cyclin-dependent kinase inhibitor palbociclib to…”
Get full text

Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference by Llovet, Josep M., Villanueva, Augusto, Marrero, Jorge A., Schwartz, Myron, Meyer, Tim, Galle, Peter R., Lencioni, Riccardo, Greten, Tim F., Kudo, Masatoshi, Mandrekar, Sumithra J., Zhu, Andrew X., Finn, Richard S., Roberts, Lewis R.

Get full text

Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond by Raoul, Jean-Luc, Kudo, Masatoshi, Finn, Richard S., Edeline, Julien, Reig, Maria, Galle, Peter R.

“…•Sorafenib is indicated for advanced and intermediate (post-TACE failure) HCC.•Sorafenib should be given early to ensure patients can benefit from all…”
Get full text

Development of Molecularly Targeted Therapies in Hepatocellular Carcinoma: Where Do We Go Now? by Finn, Richard S

“…Hepatocellular carcinoma (HCC), once considered an orphan disease in the West, has become a global health concern. It is the third leading cause of cancer…”
Get full text

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study by Finn, Richard S, MD, Crown, John P, Prof, Lang, Istvan, MD, Boer, Katalin, MD, Bondarenko, Igor M, Prof, Kulyk, Sergey O, MD, Ettl, Johannes, MD, Patel, Ravindranath, MD, Pinter, Tamas, MD, Schmidt, Marcus, MD, Shparyk, Yaroslav, MD, Thummala, Anu R, MD, Voytko, Nataliya L, MD, Fowst, Camilla, MD, Huang, Xin, PhD, Kim, Sindy T, BS, Randolph, Sophia, MD, Slamon, Dennis J, Prof

“…Summary Background Palbociclib (PD-0332991) is an oral, small-molecule inhibitor of cyclin-dependent kinases (CDKs) 4 and 6 with preclinical evidence of…”
Get full text

Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice by DeMichele, Angela, Cristofanilli, Massimo, Brufsky, Adam, Liu, Xianchen, Mardekian, Jack, McRoy, Lynn, Layman, Rachel M, Emir, Birol, Torres, Mylin A, Rugo, Hope S, Finn, Richard S

“…Findings from randomized clinical trials may have limited generalizability to patients treated in routine clinical practice. This study examined the…”
Get full text

A Novel Prognostic Nomogram Accurately Predicts Hepatocellular Carcinoma Recurrence after Liver Transplantation: Analysis of 865 Consecutive Liver Transplant Recipients by Agopian, Vatche G., MD, Harlander-Locke, Michael, MPH, Zarrinpar, Ali, MD, PhD, Kaldas, Fady M., MD, FACS, Farmer, Douglas G., MD, FACS, Yersiz, Hasan, MD, Finn, Richard S., MD, Tong, Myron, MD, Hiatt, Jonathan R., MD, FACS, Busuttil, Ronald W., MD, PhD, FACS

“…Background Although radiologic size criteria (Milan/University of California, San Francisco [UCSF]) have led to improved outcomes after liver transplantation…”
Get full text

SRC: A Century of Science Brought to the Clinic by Aleshin, Alexey, Finn, Richard S.

“…The SRC family kinases are the largest family of norreceptor tyrosine kinases and one of the best-studied targets for cancer therapy. SRC, arguably the oldest…”
Get full text

Identification of a Therapeutic Strategy Targeting Amplified FGF19 in Liver Cancer by Oncogenomic Screening by Sawey, Eric T., Chanrion, Maia, Cai, Chunlin, Wu, Guanming, Zhang, Jianping, Zender, Lars, Zhao, Alice, Busuttil, Ronald W., Yee, Herman, Stein, Lincoln, French, Dorothy M., Finn, Richard S., Lowe, Scott W., Powers, Scott

“…We screened 124 genes that are amplified in human hepatocellular carcinoma (HCC) using a mouse hepatoblast model and identified 18 tumor-promoting genes,…”
Get full text

Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study by LLOVET, Josep M, DECAENS, Thomas, MATHURIN, Philippe, FARTOUX, Laetitia, LIN, Deng-Yn, BRUIX, Jordi, POON, Ronnie T, SHERMAN, Morris, BLANC, Jean-Frédéric, FINN, Richard S, TAK, Won-Young, YEE CHAO, RAOUL, Jean-Luc, EZZEDDINE, Rana, LIU, David, WALTERS, Ian, PARK, Joong-Won, BOUCHER, Eveline, KUDO, Masatoshi, CHANG, Charissa, KANG, Yoon-Koo, ASSENAT, Eric, LIM, Ho-Yeong, BOIGE, Valerie

“…Brivanib is a selective dual inhibitor of vascular endothelial growth factor and fibroblast growth factor receptors implicated in tumorigenesis and…”
Get full text

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro by Finn, Richard S, Dering, Judy, Conklin, Dylan, Kalous, Ondrej, Cohen, David J, Desai, Amrita J, Ginther, Charles, Atefi, Mohammad, Chen, Isan, Fowst, Camilla, Los, Gerret, Slamon, Dennis J

“…Alterations in cell cycle regulators have been implicated in human malignancies including breast cancer. PD 0332991 is an orally active, highly selective…”
Get full text

Radiofrequency ablation of hepatocellular carcinoma as bridge therapy to liver transplantation: A 10‐year intention‐to‐treat analysis by Lee, Min Woo, Raman, Steven S., Asvadi, Nazanin H., Siripongsakun, Surachate, Hicks, Robert M., Chen, Jeffrey, Worakitsitisatorn, Akeanong, McWilliams, Justin, Tong, Myron J., Finn, Richard S., Agopian, Vatche G., Busuttil, Ronald W., Lu, David S.K.

“…In a long‐term (10‐year) study of radiofrequency ablation (RFA) of hepatocellular carcinoma (HCC) as bridging therapy in patients listed for orthotopic liver…”
Get full text

Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study by FINN, Richard S, BENGALA, Carmelo, IBRAHIM, Nuhad, ROCHE, Henri, SPARANO, Joseph, STRAUSS, Lewis C, FAIRCHILD, Justin, SY, Oumar, GOLDSTEIN, Lori J

“…Dasatinib is a potent, oral SRC-family kinase inhibitor with preclinical antiproliferative, antimetastatic, and antiosteoclastic activity suggesting dasatinib…”
Get full text

Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies by Ettl, Johannes, Im, Seock-Ah, Ro, Jungsil, Masuda, Norikazu, Colleoni, Marco, Schnell, Patrick, Bananis, Eustratios, Lu, Dongrui R, Cristofanilli, Massimo, Rugo, Hope S, Finn, Richard S

“…Palbociclib improves outcomes for women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer (HR+/HER2-…”
Get full text